A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib

Acquired resistance to second generation BRAF inhibitors (BRAFis), like vemurafenib is limiting the benefits of long term targeted therapy for patients with malignant melanomas that harbor BRAF V600 mutations. Since many resistance mechanisms have been described, most of them causing a hyperactivati...

Full description

Saved in:
Bibliographic Details
Published in:EBioMedicine
Main Authors: Sinnberg, Tobias, Makino, Elena, Krueger, Marcel A., Velic, Ana, Macek, Boris, Rothbauer, Ulrich, Groll, Nicola, Pötz, Oliver, Czemmel, Stefan, Niessner, Heike, Meier, Friedegund, Ikenberg, Kristian, Garbe, Claus, Schittek, Birgit
Format: Artigo
Language:Inglês
Published: Elsevier 2016
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4919613/
https://ncbi.nlm.nih.gov/pubmed/27428425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2016.04.037
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items